- Home
- VRCA
as 07-29-2025 4:00pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 80.7M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 75.1K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.82 - $73.30 | Next Earning Date: | 08-13-2025 |
| Revenue: | $7,179,000 | Revenue Growth: | -19.45% |
| Revenue Growth (this year): | 165.25% | Revenue Growth (next year): | 80.06% |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?
GlobeNewswire
2 months ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Thomson Reuters StreetEvents
3 months ago
Q1 2025 Verrica Pharmaceuticals Inc Earnings Call
GuruFocus.com
3 months ago
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...
Zacks
3 months ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
3 months ago
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Zacks
3 months ago
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
GuruFocus.com
3 months ago
Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.